Optimizing the Management of Asthma: The Critical Role of the Pharmacist

Supported by an educational grant from Teva Pharmaceuticals.

Optimizing the Management of Asthma: The Critical Role of the Pharmacist

Kyle R. Copeland, PharmDClinical Specialist PharmacistParkwest Medical CenterKnoxville, TennesseeAssociate ProfessorUniversity of Tennessee College of PharmacySouth College of PharmacyKnoxville, TennesseeDisclosuresThe following contributors have no relevant financial relationships with commercial interests to disclose.FacultyKyle R. Copeland, PharmDPharmacy Times Office of Continuing Professional Education Planning Staff—David Heckard; Maryjo Dixon, RPh; Donna Fausak; and Nathalie HardenPharmacy Times Editorial StaffBea Riemschneider and Kirk McKayAn anonymous peer reviewer was part of the content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercialinterests to disclose.

Educational Objectives

Educational ObjectivesAt the conclusion of this educational activity, participants should be able to:1. Review current management of asthma, including the most current guideline recommendations, control based on severity and age group, and emerging treatments.2. Explore the use of diagnostic and patient assessment tools to monitor response to treatment.3. Discuss the recognition of patients with difficult-to-treat asthma, and options for treatment.4. Address the pharmacist’s role in patient education and the importance of sustained proper inhaler technique and medication adherence.Target audience: PharmacistsType of activity: KnowledgeRelease date: June 20, 2014Expiration date: June 20, 2016Estimated time to complete activity: 2.0 hours

Click here to view this activity.

Click here to view this activity.

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-14-058-H01-P. The activity is available for CE credit through June 20, 2016.